3,508 results on '"O’Connor, Christopher M."'
Search Results
2. Utilizing Quality of Life Adjusted Days Alive and Out of Hospital in Heart Failure Clinical Trials
3. Optimal Medical Therapy and Outcomes Among Patients With Chronic Heart Failure With Reduced Ejection Fraction
4. Clinical Trial Inclusion and Impact on Early Adoption of Medical Innovation in Diverse Populations
5. Design and Rationale for the Direct Oral Anticoagulant Apixaban in Left Ventricular Assist Devices (DOAC LVAD) Study
6. Recurrent Hospitalizations and Response to Vericiguat in Heart Failure and Reduced Ejection Fraction
7. Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials JACC Review Topic of the Week
8. Prognostic Impact of Repeated NT-proBNP Measurements in Patients With Heart Failure With Reduced Ejection Fraction
9. Left Ventricular Ejection Fraction and the Future of Heart Failure Phenotyping
10. Comparing Analytical Methods for Composite End Points in Clinical Trials: Insights from the Vericiguat Global Study in Subjects with Heart Failure With Reduced Ejection Fraction Trial
11. Standardized Definitions for Evaluation of Acute Decompensated Heart Failure Therapies: HF-ARC Expert Panel Paper
12. Classification of Heart Failure Events by Severity: Insights From the VICTORIA Trial
13. Circulating Angiokines Are Associated With Reverse Remodeling and Outcomes in Chronic Heart Failure
14. Ejection Fraction, Biomarkers, and Outcomes and Impact of Vericiguat on Outcomes Across EF in VICTORIA
15. Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus
16. Representativeness of a Heart Failure Trial by Race and Sex Results From ASCEND-HF and GWTG-HF
17. Assessment of Biomarkers of Myocardial injury, Inflammation, and Renal Function in Heart Failure With Reduced Ejection Fraction: The VICTORIA Biomarker Substudy
18. Evolution of NT-proBNP During Prerandomization Screening in VICTORIA: Implications for Clinical Outcomes and Efficacy of Vericiguat
19. Background Medical Therapy and Clinical Outcomes From the VICTORIA Trial
20. Novel Initiative Increasing GDMT Use among Patients with Heart Failure with Reduced Ejection Fraction
21. Evaluation of the hemocompatibility of the Direct Oral Anti-Coagulant apixaban in Left Ventricular Assist Devices (DOAC LVAD) Study
22. Functional and Symptomatic Clinical Trial Endpoints: The HFC-ARC Scientific Expert Panel
23. Optimal medical therapy with or without surgical revascularization and long-term outcomes in ischemic cardiomyopathy
24. Heart Failure Site-Based Research in the United States Results of the Heart Failure Society of America Research Network Survey
25. A Standardized and Regionalized Network of Care for Cardiogenic Shock
26. Sequential Evaluation of NT-proBNP in Heart Failure: Insights Into Clinical Outcomes and Efficacy of Vericiguat
27. Titration of medical therapy and clinical outcomes among patients with heart failure with reduced ejection fraction: Findings from the HF-ACTION trial
28. Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry
29. A Composite Score Summarizing Use and Dosing of Evidence-Based Medical Therapies in Heart Failure: A Nationwide Cohort Study
30. Spirituality in Patients With Heart Failure
31. Interventions for Frailty Among Older Adults With Cardiovascular Disease: JACC State-of-the-Art Review
32. Dose-limiting, adverse event–associated bradycardia with β-blocker treatment of atrial fibrillation in the GENETIC-AF trial
33. Proteomics Identify Clinical Phenotypes and Predict Functional Outcomes in Heart Failure With Preserved Ejection Fraction: Insights From VITALITY-HFpEF.
34. Five-Year Experience From a Cardiovascular Physician and Advanced Practice Providers Leadership-Development Program.
35. Cost and Value in Contemporary Heart Failure Clinical Guidance Documents
36. Clinical Implications of Negatively Adjudicated Heart Failure Events: Data From the VICTORIA Study
37. Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure
38. Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure Insights From ASCEND-HF Trial
39. The Impact of Depression on Outcomes in Patients With Heart Failure and Reduced Ejection Fraction Treated in the GUIDE-IT Trial
40. Use of win time for ordered composite endpoints in clinical trials
41. Rehabilitation Intervention in Older Patients With Acute Heart Failure With Preserved Versus Reduced Ejection Fraction
42. Clinical Outcome Predictions for the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial
43. Early diuretic strategies and the association with In-hospital and Post-discharge outcomes in acute heart failure
44. Greater Pain Severity Is Associated with Worse Outcomes in Patients with Heart Failure
45. Intercountry Differences in Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure
46. Sex Differences in Clinical Course and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure
47. Effects of Atrial Fibrillation on Heart Failure Outcomes and NT-proBNP Levels in the GUIDE-IT Trial
48. Plasma Volume Status and Its Association With In-Hospital and Postdischarge Outcomes in Decompensated Heart Failure
49. Effects of a Novel Nitroxyl Donor in Acute Heart Failure: The STAND-UP AHF Study
50. Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.